Pathology of mitochondrial encephalomyopathies

Canadian Journal of Neurological Sciences

Volumn 32, Issue 2, 2005, Pages 152-166

  Sarnat, Harvey B ^a,c   Marín García, José ^b  

^a UNIVERSITY OF CALGARY   (Canada)

^b The Molecular Cardiology and Neuromuscular Institute   (United States)

^c ALBERTA CHILDREN'S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTICONVULSIVE AGENT; ANTIMETABOLITE; ANTIVIRUS AGENT; CARNITINE; CITRATE SYNTHASE; CREATINE; CYTOCHROME C OXIDASE; GLYCOGEN; HYPOCHOLESTEROLEMIC AGENT; IMMUNOSUPPRESSIVE AGENT; LIPID; MITOCHONDRIAL DNA; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); RIBOSOME RNA; STEROID; SUCCINATE DEHYDROGENASE (UBIQUINONE); TETRAZOLIUM REDUCTASE; UBIDECARENONE; UBIQUINOL CYTOCHROME C REDUCTASE; VALPROIC ACID;

AGING; CELL ULTRASTRUCTURE; CHRONIC PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ELECTRON MICROSCOPY; ENDOTHELIUM CELL; ENZYME ACTIVITY; GENETIC ANALYSIS; GENOTYPE; GLYCOGEN STORAGE DISEASE TYPE 2; HISTOCHEMISTRY; HISTOPATHOLOGY; HUMAN; KEARNS SAYRE SYNDROME; MELAS SYNDROME; MERRF SYNDROME; MITOCHONDRIAL ENCEPHALOMYOPATHY; MUSCLE ATROPHY; MUSCLE BIOPSY; MUSCLE CELL; NERVE FIBER; NONHUMAN; PHENOTYPE; POINT MUTATION; POLYMYOSITIS; PRIORITY JOURNAL; RESPIRATORY CHAIN; REVIEW; SKIN BIOPSY; SKIN FIBROBLAST; SPINAL MUSCULAR ATROPHY; SPINOCEREBELLAR DEGENERATION; ZELLWEGER SYNDROME;

EID: 20544441278     PISSN: 03171671     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0317167100003929     Document Type: Review

References (88)

1. DiMauro S, Bonilla E, DeVivo DC. Does the patient have a mitochondrial encephalopathy? J Child Neurol 1999;14(Suppl 1):S23-S35.
2. DiMauro S, Hirano M, Kaufmann P, et al. Clinical features and genetics of myoclonic epilepsy with ragged red fibers. Adv Neurol 2002;89:217-229.
3. Darin N, Oldfors A, Moslemi A-R, Holme E, Tulinius M. Genotypes and clinical phenotypes in children with cytochrome-c-oxidase deficiency. Neuropediatrics 2003;34:311-317.
4. Miles L, Wong B, Hofmann I, Morehart P, Bove KE. EM assessment of mitochondria correlates poorly with ETC/FAO defects in suspected disorders of energy metabolism. Lab Invest 2003 (abstract).
5. Sakuta R, Honzawa S, Murakami N, Goto Y, Nagai T. Atypical MELAS associated with mitochondrial tRNALys gene A8296G mutation. Pediatr Neurol 2002;27:397-400.
6. Melone MAB, Tessa A, Petrini S, et al. Revelation of a new mitochondrial DNA mutation (G121147A) in a MELAS/MERRF phenotype. Arch Neurol 2004;61:269-272.
7. Nishigaki Y, Tadesse S, Bonilla E, et al. A novel mitochondrial tRNALeu(UUR) mutation in a patient with features of MERRF and Kearns-Sayre syndrome. Neuromuscul Disord 2003;13:334-340.
8. Schröder R, Vielhaber S, Wiedemann FR, et al. New insights into the metabolic consequences of large-scale mtDNA deletions: a quantitative analysis of biochemical, morphological and genetic findings in human skeletal muscle. J Neuropathol Exp Neurol 2000;59:353-360.
9. Vogel H. Mitochondrial myopathies and the role of the pathologist in the molecular era. J Neuropathol Exp Neurol 2001;60:217-227.
10. Rollins S, Prayson RA, McMahon JT, Cohen BH. Diagnostic yield muscle biopsy in patients with clinical evidence of mitochondrial cytopathy. Am J Clin Pathol 2001;116:326-330.
11. Carpenter S, Karpati G. Pathology of Skeletal Muscle. 2nd ed. New York: Oxford University Press. 2001:453-459.
12. Vielhaber S, Varlamov DA, Kudina TA, et al. Expression pattern of mitochondrial respiratory chain enzymes in skeletal muscle of patients harboring the A3243G point mutation or large-scale deletions of mitochondrial DNA. J Neuropathol Exp Neurol 2002;61:885-895.
13. Oldfors A, Tulinius M. Mitochondrial encephalomyopathies. J Neuropathol Exp Neurol 2003;62:217-227.
14. Schapira AHV. Mitochondrial Function and Dysfunction. New York: Academic Press, 2003.
15. Ricoy-Campo JR, Cabello A. Mitocondriopatías. Rev Neurol (Barcelona) 2003;37:775-779.
16. Kyriakides T, Drousiotou A, Panasopoulou A, et al. A comparative morphological study in 33 cases of respiratory chain encephalomyopathies. Acta Myolog 2003;22:48-52.
17. Taylor RW, Schaefer AM, Barron MJ, McFarland R, Turnbull DM. The diagnosis of mitochondrial muscle disease. Neuromuscul Disord 2004;14:237-245.
18. Marín-García J, Goldenthal MJ, Sarnat HB. Probing striated muscle mitochondrial phenotype in neuromuscular disorders. Pediatr Neurol 2003;29:26-33.
19. Fardeau M, Tomé FMS, Rolland JC. Congenital neuromuscular disorder with predominant mitochondrial changes in type II muscle fibers. Acta Neuropathol 1981;(Suppl 7):279-282.
20. Peyronnard J-M, Charron L, Bellavance A, Marchand L. Neuropathy and mitochondrial myopathy. Ann Neurol 1980;7:262-268.
21. Yiannikas C, McLeod JG, Pollard JD, Baverstock J. Peripheral neuropathy associated with mitochondrial myopathy. Ann Neurol 1986;20:249-257.
22. McFarland R, Taylor RW, Chinnery PF, Howell N, Turnbull DM. A novel sporadic mutation in cytochrome-c-oxidase subunit II as a cause of rhabdomyolysis. Neuromuscul Disord 2004;14:162-166.
23. Schapira AHV. Primary and secondary defects of the mitochondrial respiratory chain. J Inherit Metab Dis 2002;25:207-214.
24. Tsao CY, Mendell JR, Lo WD, Luquette M, Rusin J. Mitochondrial respiratory-chain defects presenting as nonspecific features in children. J Child Neurol 2000;15:445-448.
25. Bonilla E, Schotland DL, DiMauro S, Aldover B. Electron cytochemistry of crystalline inclusions in human skeletal muscle mitochondria. J Ultrastruct Res 1975;51:404-408.
26. Bhawat AG, Ross RC. Hepatic intramitochondrial crystalloids. Arch Pathol 1971;91:70-77.
27. DiMauro S, Nicholson JF, Hays AP, et al. Benign infantile mitochondrial myopathy due to reversible cytochrome-c-oxidase deficiency. Ann Neurol 1983;14:226-234.
28. Wada H, Woo M, Nishio H, et al. Vascular involvement in benign infantile mitochondrial myopathy caused by reversible cytochrome-c-oxidase deficiency. Brain Devel 1996;18:263-268.
29. Castro-Gago M, Eirís J, Pintos E, et al. Miopatía congénita benigna asociada a deficiencia parcial de los complejos I y III de la cadena respiratoria mitocondrial. Rev Neurol (Barcelona) 2000;31:838-841.
30. Taylor RW, Birch-Machin MA, Barlett K, Turnbull DM. Succinate-cytochrome c reductase: assessment of its value in the investigation of defects of the respiratory chain. Biochim Biophys Acta 1993;116:261-265.
31. Marín-García J, Goldenthal MJ. Mitochondrial biogenesis defects and neuromuscular disorders. Pediatr Neurol 2000;22:122-129.
32. Marín-García J, Goldenthal MJ, Sarnat HB. Kearns-Sayre syndrome with a novel mitochondrial DNA deletion. J Child Neurol 2000;15:555-558.
33. Marín-García J, Goldenthal MJ, Flores-Sarnat L, Sarnat HB. Severe mitochondrial cytopathy with complete A-V block, PEO and mtDNA deletions. Pediatr Neurol 2002;27:213-216.
34. Servidei S. Mitochondrial encephalomyopathies: Gene mutations. Neuromuscul Disord 2004;14:107-116.
35. Santos JH, Hunakova L, Chen Y, Bortner C, Van Houten B. Cell-sorting experiments link persistent mitochondrial DNA damage with loss of mitochondrial membrane potential and apoptotic cell death. J Biol Chem 2003;278:1728-1734.
36. Poulton J, Deadman ME, Turnbull DM, Lake B, Gardiner RM. Detection of mitochondrial DNA deletions in blood using the polymerase chain reaction: non-invasive diagnosis of mitochondrial myopathy. Clin Genet 1991;39:33-38.
37. De Coo IF, Gussinklo T, Arts PJ, Van Oost BA, Smeets HJ. A PCR test for progressive external ophthalmoplegia and Kearns-Sayre syndrome on DNA from blood samples. J Neurol Sci 1997;149:37-40.
38. Sparaco M, Bonilla E, DiMauro S, Powers JM. Neuropathology of mitochondrial encephalomyopathies due to mitochondrial DNA defects. J Neuropathol Exp Neurol 1993;52:1-10.
39. Lake BD. Peroxisomal and mitochondrial disorders. In: Graham DI, Lantos PL, (Eds). Greenfield's Neuropathology. Arnold Press; New York, London: Oxford University Press, 2002.
40. Tanji K, Hays AP, Bonilla E. Mitochondrial alterations in ependymal cells of Kearns-Sayre syndrome. J Neuropathol Exp Neurol 2003;62:567 (abstract).
41. Sullivan PG, Dubé C, Dorenbos K, Steward O, Baram TZ. Mitochondrial uncoupling protein-2 protects the immature brain from excitotoxic neuronal death. Ann Neurol 2003;53:711-717.
42. Jordán J, Galindo MF, Tornero D, González-García C, Ceña V. Role of mitochondria in neuronal death. Rev Neurol (Barcelona) 2003;37:1058 (abstract).
43. Kubota Y, Ishii T, Sugihara H, Goto Y-I, Mizoguchi M. Skin manifestations of a patient with mitochondrial encephalomyopathy with lactic acidosis and strokelike episodes (MELAS syndrome). J Am Acad Dermatol 1999;41:469-473.
44. James AM, Wei YH, Pang CY, Murphy MP. Altered mitochondrial function in fibroblasts containing MELAS or MERRF mitochondrial DNA mutations. Biochem J 1996;318(pt 2):401-407.
45. Mandel H, Hartman C, Berkowitz D, et al. The hepatic mitochondrial DNA depletion syndrome: ultrastructural changes in liver biopsies. Hepatology 2001;34:776-784.
46. Saada A, Shaaag A, Mandel H, et al. Mutant mitochondrial thymidine kinase in mitochondrial DNA depletion myopathy. Nature Genet 2001;29:342-344.
47. Elpeleg O, Mandel H, Saada A. Depletion of the other genome-mitochondrial DNA depletion syndromes in humans. J Mol Med 2002;80:389-396.
48. Arnon S, Avram R, Dolfin T, et al. Mitochondrial DNA depletion presenting prenatally with skin edema and multisystem disease immediately after birth. Prenat Diagn 2002;22:34-37.
49. Salviati L, Sacconi S, Mancuso M, et al. Mitochondrial DNA depletion and dGK gene mutations. Ann Neurol 2002;52:311-317.
50. Mancuso M, Salviati L, Sacconi S, Otaegui D, et al. Mitochondrial DNA depletion: mutations in thymidine kinase gene with myopathy and SMA. Neurology 2002;59:1197-1202.
51. Hargreaves P, Rahman S, Guthrie P, et al. Diagnostic value of succinate ubiquinone reductase activity in the identification of patients with mitochondrial DNA depletion. J Inherit Metab Dis 2002;25:7-16.
52. Mancuso M, Filosto M, Bonilla E, et al. Mitochondrial myopathy of childhood associated with mitochondrial DNA depletion and a monozymgous mutation (T77M) in the TK2 gene. Arch Neurol 2003;60:1007-1009.
53. Marín-García J, Ananthakrishnan R, Goldenthal MJ, Filiano JJ, Pérez-Atayde A. Cardiac mitochondrial dysfunction and DNA depletion in children with hypertrophic cardiomyopathy. J Inherit Metab Dis 1997;20:674-680.
54. Holmuhamedov E, Jahangir A, Bienengraeber M, Lewis LD, Terzic A. Deletion of mtDNA disrupts mitochondrial function and structure, but not biogenesis. Mitochondrion 2003;3:13-19.
55. Naviaux RK, Nguyen KV. POLG mutations associated with Alper's syndrome and mitochondrial DNA depletion. Ann Neurol 2004;55:706-712.
56. Fernández R, Fernández JM, Cervera C, et al. Adult glycogenosis II with paracrystalline mitochondrial inclusions and Hirano bodies in skeletal muscle. Neuromuscul Disord 1999;9:136-143.
57. Pons R, Andreetta F, Wa CH, et al. Mitochondrial myopathy simulating spinal muscular atrophy. Pediatr Neurol 1996;15:153-158.
58. Berger A, Mayr JA, Meierhofer D, et al. Severe depletion of mitochondrial DNA in spinal muscular atrophy. Acta Neuropathol 2003;105:245-251.
59. Nikali K, Isosomppi J, Lonnqvist T, et al. Toward cloning of a novel ataxia gene: refined assignment and physical map of the IOSCA locus (SCA8) on 110q24. Genomics 1997;39:185-191.
60. Nikali K, Lönnqvist T, Suomalainen A, Peltonen L. Infantile onset spinocerebellar ataxia is caused by recessive mutations in a gene encoding a mitochondrial protein. Eur J Paediatr Neurol 2003;7:285 (abstract).
61. Lamperti C, Naini A, Hirano M, et al. Cerebellar ataxia and coenzyme Q10 deficiency. Neurology 2003;60:1206-1208.
62. Rifai Z, Welle S, Kamp C, Thornton CA. Ragged-red fibers in normal aging and inflammatory myopathy. Ann Neurol 1995;37:24-29.
63. Carpenter S, Karpati G, Johnston W, Shoubridge E. Coexistence of polymyositis (PM) with mitochondrial myopathy. Neurology 1992;42 (Suppl 3):388 (abstract).
64. Schuelke M, Krude H, Finckh B, et al. Septo-optic dysplasia associated with a new mitochondrial cytochrome b mutation. Ann Neurol 2002;51:388-392.
65. Sarnat HB, Machin G, Darwish HZ, Rubin SZ. Mitochondrial myopathy of cerebro-hepato-renal (Zellweger) syndrome. Can J Neurol Sci 1983;10:170-177.
66. Kelley RI. The cerebrohepatorenal syndrome of Zellweger. Morphological and metabolic aspects. Am J Med Genet 1983;16:503-517.
67. Lorenc A, Bryk J, Golik P, et al. Homoplasmic MELAS A3243G mtDNA mutation in a colon cancer sample. Mitochondrion 2003;3:119-124.
68. Wu S-P, Shuy M-K, Liou H-H, Gau C-S, Lin C-J. Interaction between anticonvulsants and human placental carnitine transporter. Epilepsia 2004;45:204-210.
69. Yerroum M, Pham-Dang C, Authier F-J, et al. Cytochrome c oxidase deficiency in the muscle of patients with zidovudine myopathy is segmental and affects both mitochondrial DNA- and nuclear DNA-encoded subunits. Acta Neuropathol 2000;100:82-86.
70. Phillips PS, Haas RH, Bannykh S, et al. Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med 2002;137:581-585.
71. Silver MA, Langsjoen PH, Szabo S, Patil H, Zelinger A. Statin cardiomyopathy? A potential role for Co-Enzyme Q10 therapy for statin-induced changes in diastolic LV performance: description of a clinical protocol. Biofactors 2003;18:125-127.
72. Melegh B, Trombitás K. Valproate treatment induces lipid globule accumulation with ultrastructural abnormalities of mitochondria in skeletal muscles. Neuropediatrics 1997;28:257-261.
73. Mitsui T, Umaki Y, Nagasawa M, et al. Mitochondrial damage in patients with long-term corticosteroid therapy: development of oculoskeletal symptoms similar to mitochondrial disease. Acta Neuropathol 2002;104:260-266.
74. Naumann M, Reiners K, Gold R, et al. Mitochondrial dysfunction in adult-onset myopathies with structural abnormalities. Acta Neuropathol 1995;89:152-157.
75. Johnston W, Karpati G, Carpenter S, et al. Late-onset mitochondrial myopathy. Ann Neurol 1995;37:16-23.
76. Grau JM, Casademont J, Cardellach F, Fernández-Solá J. Aging and mitochondrial abnormalities. Ann Neurol 1995;38:273-274 (letter).
77. Brierley EJ, Johnson MA, Bowman A, et al. Mitochondrial function in muscle from elderly athletes. Ann Neurol 1997;41:114-116.
78. Brierley EJ, Johnson MA, Lightowlers RN, et al. Role of mitochondrial DNA mutations in human aging: implications for the central nervous system and muscle. Ann Neurol 1998;43:217-223.
79. Kimata KG, Gordan L, Ajax ET, et al. A case of late-onset MELAS. Arch Neurol 1998;55:722-725.
80. Chow CK. Vitamin E regulation of mitochondrial superoxide generation. Biol Signals Recept 2001;10:112-124.
81. Komura K, Hobbiebrunken E, Ekkehard KG, Wilichowski KG, Hanefeld FA. Effectiveness of creatine myohydrate in mitochondrial encephalomyopathies. Pediatr Neurol 2003;28:53-58.
82. Matthews PM, Ford B, Dandurand RJ, et al. Coenzyme Q10 with multiple vitamins is generally ineffective in treatment of mitochondrial disease. Neurology 1993;43:884-890.
83. Li X, May MM. Location and recycling of mitochondrial α-tocopherol. Mitochondrion 2003;3:29-38.
84. Linnane AW, Kopsidas G, Zhang C, et al. Cellular redox activity of coenzyme Q10: effect of CoQ10 supplementation on human skeletal muscle. Free Radical Res 2002;36:445-453.
85. Geromel V, Darin N, Chrétien D, et al. Coenzyme Q(10) and idebenone in the therapy of respiratory chain diseases: rationale and comparative benefits. Mol Genet Metabol 2002;77:21-30.
86. Van Maldergem L, Trijbels F, DiMauro S, et al. Coenzyme Q-responsive Leigh's encephalopathy in two sisters. Ann Neurol 2002;52:750-754.
87. Huang CC, Kuo HC, Chu CC, Kao LY. Rapid visual recovery after coenzyme Q10 treatment of Leber hereditary optic neuropathy (comment). J Neuroophthalmol 2002;22:66.
88. Thomas L. Organelles as organisms. In: The Life of a Cell. New York: Viking Press, 1974:72.